Lambert-Eaton Myasthenic Syndrome (LES)

http://norml.org/news/2015/02/05/portland-norml-responds-to-olcc-s-first-meeting-on-implementation-of-measure-91-marijuana-legalization

S&P 500 2,037 +15.99 +0.79% PRESS RELEASE Catalyst Pharmaceuticals Announces Encouraging Pre-NDA Meeting With the FDA for Firdapse(TM) as a Treatment for Lambert-Eaton Myasthenic Syndrome (LEMS) By Published: Feb 2, 2015 8:03 a.m. ET SHARE   CORAL GABLES, Fla., Feb 02, 2015 (GLOBE NEWSWIRE via COMTEX) -- Catalyst Pharmaceutical Partners, Inc. CPRX, +0.00% (Catalyst Pharmaceuticals), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced it has held a productive pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) regarding Firdapse™ for the treatment of LEMS. Based on this meeting, Catalyst believes that its Phase 3 clinical program will provide acceptable support for submission of an NDA for Firdapse™ for LEMS. The Company plans to complete a full NDA submission during the 3rd quarter of 2015. Catalyst will confirm the overall regulatory path for